Edgar Filing: FOREST LABORATORIES INC - Form 425

FOREST LABORATORIES INC Form 425 June 27, 2014

Filed by Forest Laboratories, Inc.

Pursuant to Rule 425 under the Securities Act of 1933

and deemed filed pursuant to Rule 14a-12

of the Securities Exchange Act of 1934

Subject Company: Forest Laboratories, Inc.

Form S-4 File No.: 333-194781

Set forth below is an e-mail message that was made available to employees of Forest Laboratories, Inc. on June 27, 2014:

Forest Colleagues,

Beginning on the day that the acquisition of Forest by Actavis closes, you will see a new homepage when you open your internet browser. Your new default homepage will be **www.OurWinningWay.com.**

OurWinningWay.com is an Actavis web site focused on showcasing and celebrating employee culture, events and achievements. Through compelling stories, photography, video and other multimedia, the site demonstrates the power of Challenge, Connect and Commit in driving the Company s success. OurWinningWay.com is updated regularly by Actavis Corporate Communications and encourages story ideas/submissions from employees and teams across the Company. Because the site requires no user ID or password, employees are welcome to share with family, friends, customers and key stakeholders. If you would like to submit a story idea, photo, video or other content post-close, please contact Actavis Corporate Communications at Corporate.Communications@actavis.com

Accessing the Forest Enterprise Portal

Rest assured that you will continue to have easy access to the **Forest Enterprise Portal**. As you will generally continue to perform your job as you normally would, you will also need ongoing access to many applications, systems and resources on the Forest Enterprise Portal. To ensure easy navigation to the Forest Portal, we have added a link to your Favorites, as indicated below.

Simply click the gold star and then click Forest Enterprise Portal.

If your Favorites Bar is displayed, you will also see a quick link to the Portal for one-click access.

If you have any technical issues, please contact the Global Service Desk:

Informatics Service Desk:

Edgar Filing: FOREST LABORATORIES INC - Form 425

(866) 998-HELP (4357) or x27777

Service.Desk@frx.com

Important Information for Investors and Shareholders

This communication does not constitute an offer to sell or the solicitation of an offer to buy any securities or a solicitation of any vote or approval, nor shall there be any sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. In connection with the proposed merger between Actavis and Forest, Actavis has filed with the Securities and Exchange Commission (the SEC) a registration statement on Form S-4 that includes a preliminary joint proxy statement of Actavis and Forest that also constitutes a preliminary prospectus of Actavis. The registration statement is not yet effective. The definitive joint proxy statement/prospectus will be delivered to shareholders of Actavis and Forest, INVESTORS AND SECURITY HOLDERS OF ACTAVIS AND FOREST ARE URGED TO READ THE DEFINITIVE JOINT PROXY STATEMENT/PROSPECTUS AND OTHER DOCUMENTS THAT HAVE BEEN OR WILL BE FILED WITH THE SEC CAREFULLY AND IN THEIR ENTIRETY BECAUSE THEY CONTAIN OR WILL CONTAIN IMPORTANT INFORMATION. Investors and security holders may obtain free copies of the registration statement and the joint proxy statement/prospectus and other documents filed with the SEC by Actavis and Forest through the website maintained by the SEC at http://www.sec.gov. Copies of the documents filed with the SEC by Actavis may be obtained free of charge on Actavis internet website at www.actavis.com or by contacting Actavis Investor Relations Department at (862) 261-7488. Copies of the documents filed with the SEC by Forest may be obtained free of charge on Forest s internet website at www.frx.com or by contacting Forest s Investor Relations Department at (212) 224-6713.

Participants in the Merger Solicitation

Actavis, Forest, their respective directors and certain of their executive officers and employees may be considered participants in the solicitation of proxies in connection with the proposed transaction. Information regarding the persons who may, under the rules of the SEC, be deemed participants in the solicitation of the Actavis and Forest shareholders in connection with the proposed merger and a description of their direct and indirect interests, by security holdings or otherwise, is set forth in the preliminary joint proxy statement/ prospectus. Information about the directors and executive officers of Forest is set forth in its proxy statement for its 2013 annual meeting of stockholders, which was filed with the SEC on July 8, 2013, and certain of its Current Reports on Form 8-K. Information about the directors and executive officers of Actavis is set forth in Actavis, Inc. s proxy statement for its 2013 annual meeting of stockholders, which was filed with the SEC on March 29, 2013, and certain of its Current Reports on Form 8-K.

Forest Cautionary Statement Regarding Forward-Looking Statements

This communication contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include, but are not limited to, statements about the benefits of the acquisition of Forest by Actavis, including future financial and operating results, Forest s or Actavis plans, objectives, expectations and intentions and the expected timing of completion of the transaction. It is important to note that Forest s goals and expectations are not predictions of actual performance. Actual results may differ materially from Forest s current expectations depending upon a number of factors affecting Forest s business, Actavis business and risks associated with acquisition transactions. These factors include, among others, the inherent uncertainty associated with financial projections; restructuring in connection with, and successful closing of, the acquisition; subsequent integration of the companies and the ability to recognize the anticipated synergies and benefits of the acquisition; the ability to obtain required regulatory approvals for the transaction (including the approval of antitrust authorities necessary to complete the acquisition), the timing of obtaining such approvals and the risk that such approvals may result in the imposition of conditions that could adversely affect the combined company or the expected benefits of the transaction; the ability to obtain the requisite Forest and Actavis shareholder approvals; the risk that a

Edgar Filing: FOREST LABORATORIES INC - Form 425

condition to closing of the acquisition may not be satisfied on a timely basis or at all; the failure of the proposed transaction to close for any other reason; risks relating to the value of the Actavis shares to be issued in the transaction; access to available financing (including financing for the acquisition or refinancing of Forest or Actavis debt) on a timely basis and on reasonable terms; the difficulty of predicting FDA approvals, the acceptance and demand for new pharmaceutical products, the impact of competitive products and pricing, the timely development and launch of new products, and the risk factors listed from time to time in Forest Laboratories Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and any subsequent SEC filings. Forest assumes no obligation to update forward-looking statements contained in this release to reflect new information or future events or developments.